A novel multifunctional nanocomposite C225-conjugated Fe3O 4/Ag enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy

Acta Biochimica et Biophysica Sinica

Volumn 44, Issue 8, 2012, Pages 678-684

  Zhao, Di ^a   Sun, Xinchen ^a   Tong, Jinglong ^a   Ma, Jun ^a   Bu, Xiaodong ^a   Xu, Ruizhi ^a   Fan, Renhua ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

molecular targeted therapy; nasopharyngeal carcinoma cells; radiosensitivity; radiotherapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FERUMOXYTOL; NANOCOMPOSITE; RADIOSENSITIZING AGENT; SILVER; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ARTICLE; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NANOTECHNOLOGY; NASOPHARYNX CARCINOMA; NASOPHARYNX TUMOR; RADIATION RESPONSE; TIME; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FERUMOXYTOL; HUMANS; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR TARGETED THERAPY; NANOCOMPOSITES; NANOTECHNOLOGY; NASOPHARYNGEAL NEOPLASMS; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SILVER; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS;

EID: 84864426502     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gms051     Document Type: Article

References (31)

1. Rottey S, Madani I, Deron P and Van Belle S. Modern treatment for naso-pharyngeal carcinoma: current status and prospects. Curr Opin Oncol 2011, 23: 254-258.
2. Lapeyre M, Belliere A, Hoffstetter S and Peiffert D. Brachytherapy for head and neck cancers (nasopharynx excluded). Cancer Radiother 2008, 12: 515-521.
3. Chan AT. Nasopharyngeal carcinoma. Ann Oncol 2010, 21(Suppl. 7): i308-i312.
4. Tang G, Earl MA, Luan S, Wang C, Mohiuddin MM and Yu CX. Comparing radiation treatments using intensity-modulated beams, multiple arcs, and single arcs. Int J Radiat Oncol Biol Phys 2010, 76: 1554-1562.
5. Chung YC, Chen IH and Chen CJ. The surface modification of silver nanoparticles by phosphoryl disulfides for improved biocompatibility and intracellular uptake. Biomaterials 2008, 29: 1807-1816.
6. Verma A, Uzun O, Hu Y, Hu Y, Han HS, Watson N and Chen S, et al. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat Mater 2008, 7: 588-595.
7. Cedervall T, Lynch I, Lindman S, Berggard T, Thulin E, Nilsson H and Dawson KA, et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparti-cles. Proc Natl Acad Sci U S A 2007, 104: 2050-2055. (Pubitemid 46391350)
8. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T and Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A 2008, 105: 14265-14270.
9. Naumann RW. The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer. Gynecol Oncol 2011, 123: 411-420.
10. Herchenhorn D and Ferreira CG. Targeting epidermal growth factor receptor to optimize chemoradiotherapy in locally advanced head and neck cancer: has biology been taken into account? J Clin Oncol 2011, 29: e283-e284, e285-e287.
11. Lurje G and Lenz HJ. EGFR signaling and drug discovery. Oncology-Basel 2009, 77: 400-410.
12. Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ and Crowe JP, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and over-express HER2 or EGFR. Am J Surg Pathol 2006, 30: 1097-1104. (Pubitemid 44299342)
13. Perez EA and Spano JP. Current and emerging targeted therapies for meta-static breast cancer. Cancer 2012, 118: 3014-3025.
14. Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L and Liewehr DJ, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008, 100: 1092-1103.
15. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB and Jones CU, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354: 567-578. (Pubitemid 43209104)
16. Liu L, Ni F, Zhang J, Jiang X, Lu X, Guo Z and Xu R. Silver nanocrystals sensitize magnetic-nanoparticle-mediated thermo-induced killing of cancer cells. Acta Biochim Biophys Sin 2011, 43: 316-323.
17. Pajonk F, Vlashi E and McBride WH. Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells 2010, 28: 639-648.
18. Kainz K, Chen GP, Chang YW, Prah D, Sharon QX, Shukla HP and Stahl J, et al. A planning and delivery study of a rotational IMRT technique with burst delivery. Med Phys 2011, 38: 5104-5118.
19. Hoffman JM and Gambhir SS. Molecular imaging: the vision and opportunity for radiology in the future. Radiology 2007, 244: 39-47. (Pubitemid 46981957)
20. Hauger O, Frost EE, van Heeswijk R, Deminiere C, Xue R, Delmas Y and Combe C, et al. MR evaluation of the glomerular homing of magnetically labeled mesenchymal stem cells in a rat model of nephropathy. Radiology 2006, 238: 200-210. (Pubitemid 43010597)
21. Barnett BP, Arepally A, Karmarkar PV, Qian D, Gilson WD, Walczak P and Howland V, et al. Magnetic resonance-guided, real-time targeted delivery and imaging of magnetocapsules immunoprotecting pancreatic islet cells. Nat Med 2007, 13: 986-991. (Pubitemid 47222036)
22. Tai JH, Foster P, Rosales A, Feng B, Hasilo C, Martinez V and Ramadan S, et al. Imaging islets labeled with magnetic nanoparticles at 1.5 Tesla. Diabetes 2006, 55: 2931-2938. (Pubitemid 44923630)
23. Politi LS. MR-based imaging of neural stem cells. Neuroradiology 2007, 49: 523-534. (Pubitemid 46864000)
24. Dave SR and Gao X. Monodisperse magnetic nanoparticles for biodetec-tion, imaging, and drug delivery: a versatile and evolving technology. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009, 1: 583-609.
25. Fujita H. New horizons in MR technology: RF coil designs and trends. Magn Reson Med Sci 2007, 6: 29-42.
26. Laurent S, Boutry S, Mahieu I, Vander EL and Muller RN. Iron oxide based MR contrast agents: from chemistry to cell labeling. Curr Med Chem 2009, 16: 4712-4727.
27. Bronte G, Terrasi M, Rizzo S, Sivestris N, Ficorella C, Cajozzo M and Di Gaudio F, et al. EGFR genomic alterations in cancer: prognostic and predictive values. Front Biosci (Elite Ed) 2011, 3: 879-887.
28. Specenier P and Vermorken JB. Cetuximab in the treatment of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther 2011, 11: 511-524.
29. Nyati MK, Morgan MA, Feng FY and Lawrence TS. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006, 6: 876-885. (Pubitemid 44629899)
30. Larsen AK, Ouaret D, El OK and Petitprez A. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther 2011, 131: 80-90.
31. Hatanpaa KJ, Burma S, Zhao D and Habib AA. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 2010, 12: 675-684.